Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grauer, L. S.
Right arrow Articles by Tindall, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grauer, L. S.
Right arrow Articles by Tindall, D. J.

Journal of Andrology, Vol 17, Issue 4 353-359, Copyright © 1996 by The American Society of Andrology

JOURNAL ARTICLE

Identification of human glandular kallikrein hK2 from LNCaP cells

L. S. Grauer, M. C. Charlesworth, M. S. Saedi, J. A. Finlay, R. S. Liu, K. Kuus-Reichel, C. Y. Young and D. J. Tindall
Hybritech Incorporated, San Diego, California 92196-9006, USA.

Based on studies indicating that human glandular kallikrein (hK2) mRNA is present in the prostate, we prepared a monoclonal antibody to a synthetic peptide corresponding to the 41-56 region of hK2 to try to identify the hK2 protein. Although prostate-specific antigen (PSA) and hK2 share 80% homology, the 41-56 amino acid sequence of hK2 is only 50% homologous with PSA. A monoclonal antibody, HK1A523, was identified that demonstrates high specificity for hK2. In western blot analysis, the antibody has a 1,000-fold greater sensitivity for the detection of hK2 than for PSA. The antibody was used to probe spent media from the prostate carcinoma cell line, LNCaP. An immunoreactive species was N-terminally sequenced and identified as mature hK2. HK1A523 was also utilized to probe prostate tumor cytosols and seminal fluid where putative forms of hK2 were also identified. The hK2 protein therefore is expressed and secreted from prostate carcinoma cells.


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
C. Kapadia, A. Chang, G. Sotiropoulou, G. M. Yousef, L. Grass, A. Soosaipillai, X. Xing, D. H.C. Howarth, and E. P. Diamandis
Human Kallikrein 13: Production and Purification of Recombinant Protein and Monoclonal and Polyclonal Antibodies, and Development of a Sensitive and Specific Immunofluorometric Assay
Clin. Chem., January 1, 2003; 49(1): 77 - 86.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. A. Finlay, J. R. Day, C. L. Evans, R. Carlson, K. Kuus-Reichel, L. S. Millar, S. D. Mikolajczyk, M. Goodmanson, G. G. Klee, and H. G. Rittenhouse
Development of a Dual Monoclonal Antibody Immunoassay for Total Human Kallikrein 2
Clin. Chem., July 1, 2001; 47(7): 1218 - 1224.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Zhang, M.-L. Hsieh, W. Zhu, G. G. Klee, D. J. Tindall, and C. Y. F. Young
Interactive Effects of Triiodothyronine and Androgens on Prostate Cell Growth and Gene Expression
Endocrinology, April 1, 1999; 140(4): 1665 - 1671.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
M. S. Saedi, T. M. Hill, K. Kuus-Reichel, A. Kumar, J. Payne, S. D. Mikolajczyk, R. L. Wolfert, and H. G. Rittenhouse
The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia
Clin. Chem., October 1, 1998; 44(10): 2115 - 2119.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by The American Society of Andrology.